EyePoint Pharmaceuticals

EYPTApproved

EyePoint Pharmaceuticals is focused on redefining the treatment paradigm for serious retinal diseases by creating best-in-class, durable therapies that aim to improve patient outcomes while reducing treatment burden. The company leverages its proprietary Durasert E™ sustained-release technology, which has a proven safety profile across four FDA-approved products. Its lead pipeline asset, DURAVYU™ (vorolanib in Durasert E™), is a novel multi-mechanism tyrosine kinase inhibitor being developed for wet AMD and DME, with pivotal trial readouts expected in 2026. EyePoint is a publicly traded company (NASDAQ: EYPT) led by an experienced team of ophthalmology and biopharmaceutical executives.

Market Cap

$1.1B

Focus

Drug Delivery

EYPT · Stock Price

USD 13.23+0.53 (+4.17%)

Historical price data

AI Company Overview

Technology Platform

Durasert E™, a proprietary bioerodible sustained-release drug delivery platform for intravitreal injection, designed to provide therapeutic drug levels for at least six months.

Pipeline Snapshot

20 drugs in pipeline, 10 in Phase 3

Drug	Indication	Stage
Dexamethasone + Prednisolone Acetate Ophthalmic	Cataract	Approved
Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)	Cataract	Approved
FAI insert + Sham injection	Non-Infectious Uveitis	Phase 3
FAI Insert administered using the Mk II inserter + FAI Insert administered using...	Non-Infectious Uveitis	Phase 3
Sham Injector + FAI Insert	Uveitis	Phase 3

Funding History

Total raised: $190M

PIPE$125MUndisclosedFeb 15, 2023

PIPE$40MUndisclosedDec 15, 2020

Series A$25MUndisclosedMar 15, 2008

FDA Approved Drugs

DEXYCU KITNDAFeb 9, 2018

Opportunities

The primary growth opportunity is the multi-billion dollar market for durable retinal disease treatments.

Success with DURAVYU™ could establish EyePoint as a leader in long-acting ophthalmology therapeutics and provide a platform for developing additional pipeline candidates (like EYP-2301) or partnering its Durasert E™ technology with other drug compounds.

Risk Factors

Key risks include clinical trial failure of lead asset DURAVYU™, regulatory rejection, intense competition from established and emerging retinal therapies, and financial constraints associated with funding late-stage trials as a pre-revenue company.

Competitive Landscape

EyePoint competes in the crowded retinal disease market against major players like Regeneron (Eylea) and Roche/Genentech (Lucentis, Vabysmo). Its differentiation lies in its clinically validated Durasert sustained-release platform and the multi-mechanism action of vorolanib, targeting both VEGF and inflammation pathways for potential extended durability and efficacy.

Publications

Patents

Pipeline

FDA Approvals